(Circulation. 2002;105:367.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
From the Program in Integrative Cardiac Metabolism, Departments of Physiology and Biophysics (E.D.L., L.T.W., J.M.O.) and Medicine (E.D.L.), University of Illinois at Chicago, the Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, College of Medicine; Tufts University School of Veterinary Medicine (R.K.K.), North Grafton, Mass; and New Jersey Medical School, UMDNJ (S.F.V.), Newark, NJ.
Correspondence to E. Douglas Lewandowski, PhD, Department of Physiology and Biophysics, MC 901, University of Illinois College of Medicine, 835 S Wolcott Ave, Chicago, IL 60612. E-mail dougl{at}uic.edu
| Abstract |
|---|
|
|
|---|
Methods and Results The left anterior descending (LAD) coronary artery was infused for 40 minutes (5 mL/min LAD) with [213C] butyrate (4 mmol/L), a short chain fatty acid (SCFA), plus [213C] glucose (10 mmol/L) in either nonischemic controls (n=4) or at the end of 5 hours of LAD flow reduction (40%, n=7). With LAD constriction, left ventricular wall thickening fell 45±8% (P<0.01). Despite glycolytic production of lactate and alanine, hypoperfused myocardium preferentially oxidized SCFA over endogenous LCFA. SCFA accounted for 63±4% (mean±SEM) of carbon units entering oxidation in both ischemic epicardium and endocardium versus only 38±4% and 40±6% in respective samples from normal myocardium (P<0.002). Unexpectedly, SCFA contributions were elevated in both endocardium and epicardium despite preserved epicardial blood flow versus a 58±9% drop in endocardial flow (P<0.05). No significant oxidation of glucose was evident, indicating that unlabeled fuels were primarily LCFA.
Conclusions Because SCFA bypass LCFA transport into mitochondria, during LAD constriction, mitochondrial capacity to oxidize fatty acid exceeds LCFA entry for oxidation. Importantly, metabolic changes were disassociated from transmural tissue perfusion. These findings suggest that signals other than oxygen availability regulate fatty acid use during hypoperfusion.
Key Words: ischemia spectroscopy hibernation
| Introduction |
|---|
|
|
|---|
To date, reduced oxidation of both glucose and LCFA during low-flow ischemia has been generally considered to be the result of negative feedback inhibition from accumulating metabolic intermediates that are not oxidized and sequester coenzyme A.47 However, evidence exists that translocation-transesterification limits fatty acid oxidation in mitochondrial preparations that are isolated from severely ischemic canine hearts.8 Thus, the role of energy substrate entry into the mitochondrial matrix must be further considered as a central factor that limits LCFA oxidation in the hibernating myocardium,9,10 aside from the reduced availability of oxygen.
This study was aimed at determining regional substrate utilization for oxidative energy production in the in vivo porcine heart subjected to coronary artery constriction during infusion of a short chain fatty acid to fuel ß-oxidation while bypassing the highly regulated transport of LCFA. The results offer surprising, new considerations in understanding the metabolic mechanisms that limit fatty acid oxidation in an in vivo model of coronary artery constriction that is consistent with short-term, hibernating myocardium.
| Methods |
|---|
|
|
|---|
Experimental Protocols
The open chest heart preparation was subjected to either a 5-hour left anterior descending (LAD) coronary artery constriction protocol (n=7) or a 5-hour protocol without constriction as control (n=5). An LAD constriction was induced in experimental groups with a hydraulic occluder, reducing flow by
40%. The degree of coronary blood flow reduction was continuously monitored and sustained for 5 hours. In the nonischemic, control group, a 5-hour protocol controlled for potential effects of the duration of the experiment. For both groups, infusion of labeled substrates was initiated at 4 hours and 20 minutes into the protocol.
Labeled substrate, [213C] glucose (10 mmol/L), and [2,413C2] butyrate, a short chain fatty acid (4 mmol/L) in saline were infused into the coronary artery catheter proximal to the occluder during the final 40 minutes of each protocol. Labeled butyrate was chosen as a metabolic probe of fatty acid oxidation to bypass LCFA transport into mitochondria.13 Although 13C labeling studies have used acetate,14 butyrate is a fatty acid that enters ß-oxidation13 and does not increase coronary flow as does acetate (data not shown), a known vasodilator.15 An infusion pump was used to deliver the labeled substrates at 5 mL/min per 25 mL/min of measured flow through the LAD, so that the infusion was always 20% of blood flow for 40 minutes. This time period was conservative in the intent to establish steady-state isotope enrichment.14
Myocardial oxygen consumption was determined with a blood gas machine (ABL 725, Radiometer Copenhagen) and calculated as oxygen uptake (volume percent from A-V difference) multiplied by mean coronary blood flow (mL/min). Regional myocardial blood flow measurement with radioactive microspheres11 was administered at baseline, twice during LAD constriction before substrate infusion (30 minutes and just before substrate infusion), and again during constriction with substrate infusion (20-minute infusion).
At 5 hours, during continued infusion, a section of the anterior left ventricular (LV) wall was excised, divided rapidly into endocardial and epicardial segments, and freeze-clamped in liquid nitrogen, all in less than 30 seconds. An additional experiment was performed in an open chest pig receiving a 40-minute infusion to determine the effects of transmural sectioning on the excised tissue before freezing. In unsectioned tissue, lactate was 1.9±0.4 µmol/g dry wt versus values in sectioned myocardium of 1.7 in endocardium and 1.2 in epicardium. Thus, sectioning did not introduce any significant degree of incidental ischemia that may have influenced the measurements.
Additional experiments, both control (n=3) and LAD constriction (n=4), were performed over the 4-hour and 20-minute interval for tissue sampling and triglyceride assay. This sampling time provided information on the metabolic state of the myocardium at the time corresponding to the infusion protocol.
In Vitro Nuclear Magnetic Resonance Spectroscopy and Tissue Chemistry
Tissue metabolites were extracted from frozen ventricle with the use of 7% perchloric acid and assayed according to published methods.1618 Triglyceride content was determined from glycerol release after saponification of isolated lipids.19
The respective labeling patterns produced by metabolism of labeled butyrate and labeled glucose are shown in Figure 1. In vitro nuclear magnetic resonance (NMR) data were collected on a 9.4-T NMR system (Bruker Instruments).16,17 To ensure that differences in relaxation times between 13C at the 5-carbon position of glutamate versus that of the 2-,3-, and 4-carbon positions did not account for the lack of signal from 13C at the 5-carbon resonance frequency, spectra were run under fully relaxed conditions (interpulse interval=5xT1) with 90° pulse angles (with broadband proton decoupling). The percentage of labeled acetyl groups entering the Krebs cycle (Fc) was determined from the relative signal intensities and multiplet peaks of the glutamate 4- and 3-carbon resonance signals with the use of established methods13,20,21 and given by C3/C-4=1/(2y+1) and C4 doublet/C-4=Fc (2y+1), where y is the ratio of anaplerosis to citrate synthase flux.
|
Statistical Analysis
Intergroup comparisons were performed with the Students unpaired, 2-tailed t test for two groups and the ANOVA test of variance for 3 or more groups. Differences between mean values were considered statistically significant at a probability level of P<0.05.
| Results |
|---|
|
|
|---|
|
|
During constriction, regional oxygen use dropped from a preischemic baseline of 1.4±0.2 mL/min (% volume) to a value at 4 hours of hypoperfusion of 1.0±0.2 (P<0.003). This 29% reduction in oxygen use remained unchanged at the midpoint of the 40-minute infusion with labeled substrates (1.0±0.2 at 4.3 hours).
Oxidative and Nonoxidative Metabolism
13C NMR spectra from myocardial extracts displayed the expected increases in signals from glycolytic end products in the ischemic tissue (Figure 4), whereas signals from glutamate indicated active oxidation of the short chain fatty acid. Despite nonoxidative glycolytic metabolism in the ischemic myocardium, short chain fatty acid oxidation was retained, albeit at the expected reduction in oxidative rate,22 with a drop in oxygen consumption during the stenosis. Figure 5 displays an expanded region of a representative 13C NMR spectrum from an extract of ischemic epicardial tissue that displays the high-resolution, multiplet structures within the resonance peaks of the 13C-enriched glutamate.20,21
|
|
Data demonstrating the 13C enrichment of glutamate caused by short chain fatty acid oxidation provided the primary results of this study: Short chain fatty acid accounted for 63±4% of acetyl-CoA produced in the mitochondria in both ischemic epicardium and endocardium versus only 46±5% and 49±5% in respective controls (P<0.002). These data (Figure 6) indicate that the hypoperfused myocardium preferentially oxidized short chain fatty acid over endogenous LCFA, in contrast to normal myocardium.
|
Even more unexpected was the finding that the epicardium and endocardium used similar contributions from short chain fatty acid despite preservation of essentially normal blood flow rates in the epicardial layer and a 58±9% reduction in endocardial blood flow. These data, shown in Figure 7, indicate that the inhibition of fatty acid entry into the mitochondria during coronary stenosis was independent of regional, transmural blood flow.
|
Increased nonoxidative, glycolytic metabolism in the ischemic hearts is confirmed by lactate and alanine content (Table). As expected, lactate was increased in ischemic tissue (Table). In control tissue, the alanine and lactate were approximately equal, whereas in ischemic tissue, lactate represented slightly more of this pool of glycolytic end products (59% in endocardium and 57% in epicardium). This distribution reflects the increased ratio of cytosolic NADH/NAD+ during ischemia.17,18
|
Glutamate content was similar at the end of both the control and ischemia protocols, indicating that the low-flow ischemia did not reduce total tissue glutamate levels that remained at steady state to enable comparisons of isotope enrichment (Table). With stenosis, substrate infusion did not affect glutamate content, as seen in comparison to saline infusion: epicardial glutamate=18 µmol/g dry weight and endocardial glutamate=13 µmol/g dry weight. A low level of glucose oxidation was demonstrated in both layers by the absence of 13C NMR signal at 182 ppm (lack of signal not shown) from the glutamate 5-carbon. As a percentage of Krebs cycle flux, anaplerosis remained similarly low in all groups (controls: epicardium=9±2%, endocardium=9±2% versus hypoperfused: epicardium=11±3%, endocardium=13±2%, NS).
Hypoperfused myocardium showed the expected increase in triglyceride content before the time of infusion of labeled substrate. Total glycerol, as triglyceride content after saponification,19 increased from a control value of 16.2±1.7 mmol/g/dry wt to 27.8±4.3 mmol/g/dry wt during ischemia (mean±SEM, P<0.04). These data prove that the relative reduction in LCFA oxidation to that of short chain fatty acid during ischemia was not due to any unexpected reduction in lipid content during hypoperfusion.
| Discussion |
|---|
|
|
|---|
Competition between the short chain fatty acid and LCFA is notable because the established literature shows that fatty acid levels increase in ischemic myocardium.2325 Consistent with these reports, endogenous triglyceride increased as a result of hypoperfusion. The importance of this approach, using exogenous short chain fatty acids to bypass LCFA utilization,13 is that if a direct measure of LCFA were performed, we would only demonstrate the known reduction in LCFA oxidation.13
The novelty of these findings is that by using a short chain fatty acid, we have elucidated a continued oxidation of fatty acids that would otherwise not be detected with labeled LCFA. The indication that butyrate contributions increased during ischemia in this study may be the result of inhibition of LCFA oxidation through CPT1, as suggested by previous work on the regulation of LCFA oxidation through malonyl CoA sensitivity in mitochondria from ischemic dog hearts.4 Alternatively, differences in the relative sensitivities of the long, medium, and short chain acyl-CoA dehydrogenases to ischemia may be reflected in these results, with the short chain acyl-CoA dehydrogenase accommodating butyrate oxidation beyond the capacity of the other dehydrogenases to support LCFA oxidation. Nonetheless, the argument remains that short chain fatty acid oxidation is preferred over the oxidation of LCFA in the hypoperfused myocardium. Two additional factors clearly implicate the entry of fatty acid into the mitochondria and subsequently ß-oxidation as the reason for the increased role of short chain fatty acids in oxidative metabolism during hypoperfusion: (1) scaling the infusion rates to account for reductions in baseline blood flow and (2) the choice of exogenous substrates in the infusion, 13C-enriched butyrate and 13C-enriched glucose.
Despite the demonstrated glycolytic metabolism, 13C NMR data show no evidence of significant oxidation of glycolytic end products in either group. This finding is not surprising, based on previous reports.26 The low level of glucose oxidation does establish that carbohydrate metabolism was not a confounding variable. It is possible that a change in glycogen breakdown occurred, but the proportion of butyrate use relative to other fuels went up, and not down. Nor are the findings obscured by potential changes in ketone levels, because this would have reduced, not increased, the contributions of the labeled short chain fatty acid.
Interestingly, both the epicardium and endocardium displayed the same elevated contributions to acetyl CoA formation from short chain fatty acid, despite preservation of normal blood flow in the epicardial layer versus a 58±9% drop in endocardial flow. These data (Figure 6) indicate that the metabolic changes during stenosis were independent of transmural blood flow. This finding suggests the intriguing concept that signals other than oxygen delivery determine fatty acid oxidation in the hypoperfused myocardium. The LAD constriction produced a 29% reduction in oxygen use by the myocardium. However, a relative increase in butyrate utilization, in comparison to the other circulating substrates, suggests a nonoxygen-mediated change in substrate selection for mitochondrial metabolism. Therefore, a potential mechanism for future consideration is the elevation of metabolic intermediates, such as malonyl-CoA, which may build up as the result of increased acetyl-CoA content in the heart as the rate of substrate oxidation slows.4,7,27 However, were availability and utilization of oxygen the sole mechanisms, then the reduced rates of oxidative metabolism would otherwise have limited short chain fatty acid oxidation in the same proportion to the other available substrates as during normal perfusion.
The findings indicate that regulation of fatty acid oxidation in a physiological preparation is more dependent on fatty acid transport than the oxidative capacity of the mitochondria. Recent work has shown that factors other than tissue oxygenation, such as nitric oxide, affect the oxidation of fatty acids.28 The results shown here indicate that mechanisms invoked during regional hypoperfusion may become important in regulating the extent of substrate oxidation in the myocardium during limited flow, even though sufficient tissue oxygenation exists to support a higher level of oxidative metabolism. Even more surprising are the changes in butyrate use that appeared to be independent of transmural blood flow. Although fatty acid accumulation has been implicated in reperfusion damage,29 fatty acid oxidation does require more oxygen than that of carbohydrates and may be a countering limitation during hypoperfusion. This apparent drop in the oxidation of endogenous LCFA, despite the ability to support short chain fatty acid oxidation, may prove to be a protective mechanism against the potential deleterious effects of high oxygen demand by lipid oxidation during low-flow conditions.30
| Acknowledgments |
|---|
Received September 24, 2001; revision received October 31, 2001; accepted November 8, 2001.
| References |
|---|
|
|
|---|
2. Matsunari I, Fujino S, Taki J, et al. Impaired fatty acid uptake in ischemic but viable myocardium identified by thallium-201 reinjection. Am Heart J. 1996; 131: 458465.[CrossRef][Medline] [Order article via Infotrieve]
3. Shimonagata T, Nanto S, Kusuoka H, et al. Metabolic changes in hibernating myocardium after percutaneous transluminal coronary angioplasty and the relation between recovery in left ventricular function and free fatty acid metabolism. Am J Cardiol. 1998; 82: 559563.[CrossRef][Medline] [Order article via Infotrieve]
4.
Pauly DF, Kirk KA, McMillin JB. Carnitine palmitoyltransferase in cardiac ischemia: a potential site for altered fatty acid metabolism. Circ Res. 1991; 68: 10851094.
5. Lopaschuk GD, Belke DD, Gamble J, et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994; 1213: 263276.[Medline] [Order article via Infotrieve]
6. Kantor PF, Dyck JRB, Lopaschuk GD. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci. 1999; 18: 314.
7.
Lewandowski ED, Metabolic mechanisms associated with antianginal therapy. Circ Res. 2000; 86: 487489.Editorial.
8.
Pauly DF, Yoon SB, McMillin JB. Carnitine-acylcarnitine translocase in ischemia: evidence for sulfhydryl modification. Am J Physiol (Heart Circ Physiol. 1987; 253: H1557H1565.
9.
Arai AE, Pantely GA, Anselone CG, et al. Active downregulation of myocardial energy requirements during prolonged moderate ischemia in swine. Circ Res. 1991; 69: 14581469.
10.
Schaefer S, Schwartz GG, Wisneski JA, et al. Response of high-energy phosphates and lactate release during prolonged regional ischemia in vivo. Circulation. 1992; 85: 342349.
11.
Kudej RK, Ghaleh B, Sato N, et al. Ineffective perfusion-contraction matching in conscious, chronically instrumented pigs with an extended period of coronary stenosis. Circ Res. 1998; 82: 11991205.
12.
Gwirtz PA. Construction and evaluation of a coronary catheter for chronic implantation in dogs. J Appl Physiol. 1986; 60: 720726.
13.
Lewandowski ED, Chari MV, Roberts R, et al. NMR studies of ß-oxidation and short chain fatty acid metabolism during recovery of reperfused hearts. Am J Physiol. 1991; 261: H354H363.
14.
Robitaille P Rath ML, Abduljalil AM, et al. Dynamic 13C NMR analysis of oxidative metabolism in the in vivo canine myocardium. J Biol Chem. 1993; 268: 2629626300.
15. Yamada N, Bunger R, Steinhart CR, et al. Coronary vasoactivity of acetate in dog and guinea-pig. Basic Res Cardiol. 1986; 81: 342349.[CrossRef][Medline] [Order article via Infotrieve]
16.
Lewandowski ED, Nuclear magnetic resonance evaluation of metabolic and respiratory support of work load in intact rabbit hearts. Circ Res. 1992; 70: 576582.
17.
Lewandowski ED, Johnston D, Roberts R. Effects of inosine on glycolysis and contracture during myocardial ischemia. Circ Res. 1991; 68: 578587.
18. Damico LA, White LY, Yu X, et al. Chemical versus isotopic equilibrium and the metabolic fate of glycolytic end products in the heart. J Mol Cell Cardiol. 1996; 28: 989999.[CrossRef][Medline] [Order article via Infotrieve]
19.
Lopaschuk GD, Hansen CA, Neel JR. Fatty acid metabolism in hearts containing elevated levels of CoA. Am J Physiol (Heart Circ Physiol). 1986; 250: H351H359.
20. Malloy CR, Thompson JR, Jeffrey FMH, et al. Contribution of exogenous substrates to acetyl coenzyme A: measurement by 13C NMR under non-steady-state conditions. Biochemisty. 1990; 29: 67566761.[CrossRef][Medline] [Order article via Infotrieve]
21. Lewandowski ED, Doumen C, White LT, et al. Multiplet structure of 13C NMR signal from glutamate and direct detection of tricarboxylic acid (TCA) cycle intermediates. Magn Reson Med. 1996; 35: 149154.[Medline] [Order article via Infotrieve]
22. Dean EN, Shalafer M, Nicklas JM. The oxygen consumption paradox of "stunned myocardium" in dogs. Basic Res Cardiol. 1990; 85: 120131.[CrossRef][Medline] [Order article via Infotrieve]
23. Burton KP, Buja LM, Sen A, et al. Accumulation of arachidonate in triacylglycerols and unesterified fatty acids during ischemia and reflow in the isolated rat heart: correlation with the loss of contractile function and the development of calcium overload. Am J Pathol. 1986; 124: 238245.[Abstract]
24. Prinzen FW, Van der Vusse GJ, Arts T, et al. Accumulation of nonesterified fatty acids in ischemic canine myocardium. Am J Physiol. 1984; 247: H264H272.
25. Hutter JF, Soboll S. Role of fatty acid metabolites in the development of myocardial ischemic damage. Int J Biochem. 1992; 24: 399403.[CrossRef][Medline] [Order article via Infotrieve]
26.
Mazer CD, Cason BA, Stanley WC, et al. Dichloroacetate stimulates carbohydrate metabolism but does not improve systolic function in ischemic pig heart. Am J Physiol (Heart Circ Physiol). 1995; 268: H879H885.
27.
McGarry JD, Leatherman GF, Foster DW. Carnitine palmitoyltransferase I: the site of inhibition of hepatic fatty acid oxidation by malonyl CoA. J Biol Chem. 1978; 253: 41284136.
28.
Recchia FA, McConnell PI, Bernstein RD, et al. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res. 1998; 83: 969979.
29.
Liedtke AJ, Nellis SH, Neely JR. Effects of excess free fatty acids on mechanical and metabolic function in normal and ischemic myocardium in swine. Circ Res. 1978; 43: 652661.
30.
Liedtke AJ, Nellis SH, Mjos OD. Effects of reducing fatty acid metabolism on mechanical function in regionally ischemic hearts. Am J Physiol (Heart Circ Physiol). 1984; 247: H387H394.
This article has been cited by other articles:
![]() |
M. N. Jameel, X. Wang, M. H. J. Eijgelshoven, A. Mansoor, and J. Zhang Transmural distribution of metabolic abnormalities and glycolytic activity during dobutamine-induced demand ischemia Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2680 - H2686. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Lewandowski, J. M. O'Donnell, T. D. Scholz, N. Sorokina, and P. M. Buttrick Recruitment of NADH shuttling in pressure-overloaded and hypertrophic rat hearts Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1880 - C1886. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. O'Donnell, R. K. Kudej, K. F. LaNoue, S. F. Vatner, and E. D. Lewandowski Limited transfer of cytosolic NADH into mitochondria at high cardiac workload Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2237 - H2242. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, A. H. L. From, K. Ugurbil, and R. J. Bache Myocardial oxygenation and high-energy phosphate levels during KATP channel blockade Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1420 - H1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Chandler, P. N. Chavez, T. A. McElfresh, H. Huang, C. S. Harmon, and W. C. Stanley Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia Cardiovasc Res, July 1, 2003; 59(1): 143 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Chavez, W. C. Stanley, T. A. McElfresh, H. Huang, J. P. Sterk, and M. P. Chandler Effect of hyperglycemia and fatty acid oxidation inhibition during aerobic conditions and demand-induced ischemia Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1521 - H1527. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Kudej, L. T. White, A. B. Kudej, S. F. Vatner, and E. D. Lewandowski Brief Increase in Carbohydrate Oxidation After Reperfusion Reverses Myocardial Stunning in Conscious Pigs Circulation, November 26, 2002; 106(22): 2836 - 2841. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |